Ritedose Awarded 503B Compounded Medications Agreement with Premier, Inc.
Ritedose, a South Carolina-based 503B outsourcing facility, has secured a group purchasing agreement with Premier Inc. (PINC), effective January 1, 2023. This agreement allows Premier members access to pre-negotiated pricing and terms for Ritedose's full range of compounded medications. Ritedose provides ready-to-use, single-dose syringe products to various healthcare organizations. Their CEO Jody Chastain highlighted their capability to meet outsourcing needs without disruptions in patient care. Premier, which collaborates with over 4,400 U.S. hospitals, aims to enhance healthcare outcomes and lower costs through integrated services.
- Secured group purchasing agreement with Premier Inc., expanding market access.
- Provides ready-to-use syringe products for healthcare organizations, enhancing service delivery.
- CEO emphasizes capacity to ensure uninterrupted supply of medications.
- None.
"We're pleased to work with
Founded in 1995 in
View original content to download multimedia:https://www.prnewswire.com/news-releases/ritedose-awarded-503b-compounded-medications-agreement-with-premier-inc-301733854.html
SOURCE
FAQ
What is the significance of the agreement between Ritedose and Premier Inc. (PINC)?
When did the agreement between Ritedose and Premier Inc. take effect?
What types of products does Ritedose provide?